This article summarized the latest R&D progress of Rufinamide, the Mechanism of Action for Rufinamide, and the drug target R&D trends for Rufinamide.

CysLT, or cysteinyl leukotrienes, are inflammatory mediators produced by various cells in the human body, including mast cells, eosinophils, and macrophages.

This article summarized the latest R&D progress of Selinexor, the Mechanism of Action for Selinexor, and the drug target R&D trends for Selinexor.

These studies focused on the outcomes of the Phase 1b/2 study carried out on patients who had relapsed/refractory multiple myeloma and were undergoing treatment with Equecabtagene Autoleucel.

This article summarized the latest R&D progress of Terbinafine hydrochloride, the Mechanism of Action for Terbinafine hydrochloride, and the drug target R&D trends for Terbinafine hydrochloride.

Antitoxin is a specific antibody or serum containing this antibody that can neutralize toxins. By using toxoids for immunization, the body can produce corresponding antitoxins to prevent diseases.

This article summarized the latest R&D progress of Thiothixene, the Mechanism of Action for Thiothixene, and the drug target R&D trends for Thiothixene.

Mabwell announced the initiation of a Phase Ib/II trial with the first patient dosage. The study uses their novel Nectin-4 ADC (9MW2821) in conjunction with a PD-1 inhibitor for advanced or metastatic urothelial carcinoma.

This article summarized the latest R&D progress of Tigecycline, the Mechanism of Action for Tigecycline, and the drug target R&D trends for Tigecycline.

Myostatin, a member of the transforming growth factor beta (TGF‐β) superfamily that is highly expressed in skeletalmuscle, was first described in 1997.

This article summarized the latest R&D progress of Trilostane, the Mechanism of Action for Trilostane, and the drug target R&D trends for Trilostane.

ImmunoGenesis announced the first patient treatment in their Phase 1a/1b trial using IMGS-001 at The University of Texas MD Anderson Cancer Center.